NL-OMON41614已完成3 期
A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer *ART DECO* - ART DECO
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •T1-4, N0-3, M0 adeno- or squamous cell carcinoma of the esophagus or esophageal gastric junction referred for definitive chemoradiation
排除标准
- •tumors > 10 cm, unfit for definitive chemoradiation, pathologic lymphnodes at both truncus coeliacus and supraclavicular level, esophageal stent in situ.
研究者
相似试验
尚未招募
不适用
Dose escalation study for inoperable esophageal cancer patients.inoperable oesophageal tumorsdefinitive chemoradiationdose escalationNL-OMON25587dept of Radiotherapy, AMC, AmsterdamArhems Radiotherapeutisch Institute, Arnhemdept of oncology, Erasmusmc, Rotterdam260
进行中（未招募）
不适用
Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study) - ONC-2006-004MedDRA version: 9.1Level: LLTClassification code 10019695Term: Hepatic neoplasmHepatocellular carcinomaEUCTR2007-000758-30-ITISTITUTO CLINICO HUMANITAS
进行中（未招募）
1 期
An investigation to investigate whether a single dose of XEN-D0501 is tolerable by type 2 diabetic patients prior to multiple dose trials (to investigate if the compound can effectively regulate diabetes)Type 2 diabetesEUCTR2016-003843-12-DKPILA PHARMA26
进行中（未招募）
不适用
A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patients Who Have Failed Standard Chemotherapy and Progressed During or Within 6 months of Stopping Cetuximab-Based Therapy. - Zalutumumab with or without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerEUCTR2007-005690-59-BEGenmab A/S97
终止
2 期
To identify the effective dose(s) of RT234 (vardenafil inhalation powder) to acutely improve pulmonary vascular haemodynamics in study participants with Pulmonary Arterial Hypertension (PAH).Cardiovascular - Other cardiovascular diseasesPulmonary Arterial HypertensionACTRN12619001178134Respira Therapeutics Australia Pty Ltd14